Lung cancer remains the leading cause of cancer deaths worldwide. Although Stage IB disease is usually managed with upfront resection, consideration for adjuvant chemotherapy treatment is dependent on the presence or absence of high risk factors. The prognostic value of these factors and survival outcomes for these patients as reported by a national database have not been clearly elucidated. Patients with diagnosed NSCLC Stage IB (pT2aN0) per AJCC 7th edition between 2010 and 2016 from the NCDB were included. Non-surgical cases and cases that received radiotherapy were excluded. Univariate analyses comparing the clinico-demographic and pathologic features of those managed with surgery and observation (obs) versus surgery and adjuvant chemotherapy (CT) was performed. Multivariate analyses identified factors that influence survival and the likelihood of receiving CT. Kaplan-Meier method was performed to compare median OS. A total of 10,669 cases (84.2% obs, 15.8% CT) were identified. The obs cohort were primarily over age 70 (50.4%); those managed with CT were primarily 50-70 years (69.3%). Cases with tumors 4-5cm (OR, 0.388, P<0.0001), pleural invasion (OR, 0.598, P<.0001), and poor tumor differentiation (OR, 0.332, P<.0001) had a decreased likelihood of receiving obs versus CT. Age over 70 (HR, 1.801, P<.0001), Medicare insurance (HR, 1.246, P<.0001), and poor tumor differentiation (HR, 1.741, p<.0001) were adverse predictors of OS for those receiving obs versus CT. Five-year survival was higher for CT (63.6%) versus obs (57.1%), median OS was 88 months versus 75 months (p<0.0001) respectively. Those with moderately differentiated tumors achieved a survival benefit of 23 months when managed with CT (Table 1). Median OS increased by 19 months (65 versus 84 months) for poorly differentiated tumors managed with CT (p<.0001). When visceral pleural invasion was present, median OS was 60 months (obs) and greater than 75 months (CT) (p=0.0006). Cases with tumors 4-5cm in size had a median OS of 88 months when CT was received versus 67 months when managed with obs (p<.0001). Cases managed with lobectomy experienced a survival benefit of 92 months (CT) and 76 months (obs) (p<.0001).Tabled 1Surgery and Observation (reference)Surgery and ChemotherapyOS Benefit (Mos)P-valueMedian OS (Mos)95% CI Lower Limit95% CI Upper LimitMedian OS (Mos)95% CI Lower Limit95% CI Upper LimitOverall7571778883NEa13<.0001No pleural involvement7875839284NE140.0026Visceral Pleural Invasion605671NE75 bNE-0.0006< lobectomy5851655243NE- 60.8810lobectomy7673789287NE16<.00013-4cm7976868774NE80.05894-5cm6762718883NE21<.0001Moderately Diff6966759292NE23<.0001Poorly Diff6560708477NE19<.0001aNE= Not estimate, small sample/sparse data bMedian OS >75 months for CT; Mos=Months CI=Confidence Interval Diff=differentiation Open table in a new tab aNE= Not estimate, small sample/sparse data bMedian OS >75 months for CT; Mos=Months CI=Confidence Interval Diff=differentiation Overall, stage IB (pT2aN0) NSCLCs managed with CT, experienced an increased median OS of 13 months when compared to the obs cohort. Cases with pleural invasion, tumors 4-5cm in size with poor differentiation might experience a survival benefit in excess of 20 months, when CT is given versus obs.
Read full abstract